Overall rank by patents
#26,478
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 5 technology areas, active 2020–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA).
The verdict
Healthstream holds 10 US patents across 5 technology areas, rank #26,478 of 50,000 tracked assignees.
Healthstream, Inc. has been granted 10 US utility patents between 2020 and 2025, placing Healthstream, Inc. at rank #26,478 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.1 claims per patent with primary concentration in G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA). As a US Corporation, Healthstream, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Healthstream sits between Hankscraft, Inc. (10 patents, rank #26,474) and Helix Biopharma Corp. (10 patents, rank #26,482) - the closest US assignees by grant volume. The composite Innovation Score of 32.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2025, with 10 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Healthstream, Inc.'s 19.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Healthstream, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Hankscraft, Inc.
10 patents
Hanover Prest-Paving Company
10 patents
Harken, Incorporated
10 patents
Haynes International, Inc.
10 patents
Hearth Hounds, LLC
10 patents
Heatworks Technologies, Inc.
10 patents
Heinrich-Heine-Universitat Dusseldorf
10 patents
Helix BioPharma Corp.
10 patents
HealthStream, Inc.
10 patents
What this shows Healthstream holds 10 patents at rank #26,478, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Healthstream's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
33 Top 58% higher than 42% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 2 | 20.0% |
| 2021 | 2 | 20.0% |
| 2022 | 1 | 10.0% |
| 2024 | 2 | 20.0% |
| 2025 | 3 | 30.0% |
Top 5 of 5 technology areas
Overall rank by patents
#26,478
Across all tracked assignees
32.6 out of 100
How to use this portfolio
Healthstream's 10 grants land it in the top 58% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.